Summary
What is already known about this topic?
The Advisory Committee on Immunization Practices currently recommends routine vaccination against 15 potentially serious illnesses for children by age 24 months.
What is added by this report?
Estimated coverage with most childhood vaccines was lower among children born during 2020–2021 (during or after the height of the health care disruption from the COVID-19 pandemic) compared with those born during 2018–2019. Disparities by race and ethnicity, health insurance status, poverty status, and urbanicity persist. Coverage also varied widely by jurisdiction, especially for influenza vaccine.
What are the implications for public health practice?
Financial barriers, access issues, vaccine hesitancy, and vaccine-related misinformation all need to be overcome to increase coverage, ensure full recovery from the impact of the COVID-19 pandemic, eliminate disparities, and protect all children from vaccine-preventable diseases.
Abstract
Data from the National Immunization Survey-Child (NIS-Child) were analyzed to estimate coverage with childhood vaccines recommended by the Advisory Committee on Immunization Practices among U.S. children by age 24 months. Coverage with nearly all vaccines was lower among children born in 2020 and 2021 than it was among those born in 2018 and 2019, with declines ranging from 1.3 to 7.8 percentage points. Analyses of NIS-Child data for earlier birth cohorts have not revealed such widespread declines in routine childhood vaccination coverage. Coverage among children born during 2020–2021 varied by race and ethnicity, health insurance status, poverty status, urbanicity, and jurisdiction. Compared with non-Hispanic White children, coverage with four of the 17 vaccine measures was lower among non-Hispanic Black or African American children as well as Hispanic or Latino (Hispanic) and non-Hispanic American Indian or Alaska Native children. Coverage was also generally lower among those covered by Medicaid or other nonprivate insurance, uninsured children, children living below the federal poverty level, and children living in rural areas. Coverage varied widely by jurisdiction, especially coverage with ≥2 doses of influenza vaccine. Children born during 2020–2021 were born during or after the period of major disruption of primary care from the COVID-19 pandemic. Providers should review children’s histories and recommend needed vaccinations during every clinical encounter. Addressing financial barriers, access issues, vaccine hesitancy, and vaccine-related misinformation can also help to increase coverage, reduce disparities, and protect all children from vaccine-preventable diseases. Strategies that have been found effective include implementation of standing orders and reminder and recall systems, strong physician recommendations to vaccinate, and use of immunization information systems to identify areas of lower coverage that could benefit from targeted interventions to increase immunization rates.
Introduction
The Vaccine National Strategic Plan* has as its vision the elimination of vaccine-preventable diseases from the United States through safe and effective vaccination. The Advisory Committee on Immunization Practices (ACIP) currently recommends routine vaccination against 15 potentially serious illnesses for children by age 24 months (1). Since 1994, the National Immunization Survey-Child (NIS-Child) has monitored coverage with ACIP-recommended childhood vaccines.† NIS-Child data are used to calculate annual vaccination coverage estimates at the national and state levels, with additional estimates for some local areas (e.g., cities and counties) and three U.S. territories (Guam, Puerto Rico, and the U.S. Virgin Islands).§ This report assesses trends in vaccination coverage by year of birth and disparities in coverage by sociodemographic characteristics. In addition, this report provides a first look at children born in 2021 (during the COVID-19 pandemic) and reaching age 24 months toward or after the end of the COVID-19 public health emergency.
Methods
Data Collection
NIS-Child uses random-digit–dialing to identify U.S. households that include a child aged 19–35 months, and interviews are conducted via mobile telephone¶ with the parent or guardian (parent) most knowledgeable about the child’s vaccination history. With parental consent, a questionnaire is mailed to each of the child’s vaccine providers to obtain detailed information about vaccines received since birth. Provider-reported data are then synthesized to create a comprehensive vaccination history for each child. For the most recent survey year (children identified in 2023), the household interview response rate** was 27.0%, and adequate provider data†† were available for 48.1% of children with completed interviews. Children born during 2020–2021 were identified using data collected during 2021–2023; a total of 28,688 subjects were available for analysis.
Data Analysis
All coverage estimates in this report are based upon information supplied by vaccination providers. Data were analyzed by birth cohort (year of birth), and for most vaccines, Kaplan-Meier techniques were used to estimate coverage by age 24 months. Exceptions include the birth dose of hepatitis B vaccine (HepB), assessed during the first 3 days of life, and the rotavirus vaccine series, which should be completed by age 8 months. Because of a change in ACIP recommendations in 2020 and a long period of eligibility for catch-up vaccination, coverage with ≥2 doses of hepatitis A vaccine (HepA) was estimated by age 35 months (the maximum age within the scope of NIS-Child data collection) as well as by age 24 months.§§ Differences in coverage estimates were evaluated using z-tests at an α-level of 0.05. Nationally and by jurisdiction, estimated coverage among children born in 2020 and 2021 was compared with estimated coverage among children born in 2018 and 2019. For data stratified by sociodemographic characteristics, subgroup estimates were compared with those for a designated referent group. Analyses used weighted data and were performed using SAS software (version 9.4; SAS Institute) and SUDAAN software (version 11; RTI International). This activity was reviewed by CDC, deemed not research, and was conducted consistent with applicable federal law and CDC policy.¶¶
Results
Recent Trends in National Vaccination Coverage by Birth Year
Estimated coverage with all recommended childhood vaccines was lower among children born in 2020 and 2021 than among those born in 2018 and 2019, except for the HepB birth dose and ≥2 doses of HepA (Table 1). Most decreases ranged from 1.3 percentage points for ≥1 dose of varicella vaccine to 3.2 percentage points for the full series of Haemophilus influenzae type b conjugate vaccine (Hib) and the combined seven-vaccine series,*** with a larger (7.8 percentage point) drop in coverage with ≥2 doses of influenza vaccine. Longer term trends by single-year birth cohort reveal decreases in coverage with ≥2 doses of influenza vaccine from the 2019 to 2020 birth cohort and from the 2020 to 2021 birth cohort (Supplementary Figure, https://stacks.cdc.gov/view/cdc/162212). Aside from declines in influenza vaccine coverage, the largest observed declines in coverage were for those vaccines and vaccine doses with recommended series completion during the second year of life (i.e., the fourth dose of diphtheria and tetanus toxoids, and acellular pertussis vaccine (DTaP), the final dose in the full Hib series, and the fourth dose of pneumococcal conjugate vaccine (PCV)). Despite the decreases, coverage with several vaccines remained above 90%, including poliovirus vaccine (91.9%); ≥1 dose of measles, mumps, and rubella vaccine (MMR) (90.3%); and ≥3 doses of HepB (91.1%) (Table 1). The lowest estimated coverage was with ≥2 doses of HepA by 24 months (46.0%), and ≥2 doses of influenza vaccine (55.6%). The percentage of children who received no vaccinations by age 24 months remained low (1.2%).
Vaccination Coverage by Selected Sociodemographic Characteristics and Jurisdictions
Disparities in coverage by race and ethnicity were observed among children born during 2020–2021 (Table 2). Coverage with ≥4 doses of DTaP, ≥4 doses of PCV, rotavirus vaccine, and the combined seven-vaccine series was lower among non-Hispanic Black or African American (Black) children, Hispanic or Latino (Hispanic) children, and non-Hispanic American Indian or Alaska Native (AI/AN) children than among non-Hispanic White (White) children. Compared with coverage among White children, coverage with ≥2 doses of influenza vaccine was lower among Black and Hispanic children but higher among non-Hispanic Asian children.
By health insurance status, coverage with all vaccines was lower among children who were covered by Medicaid or other nonprivate insurance, and those who were uninsured, than among those covered solely by private insurance (Supplementary Table 1, https://stacks.cdc.gov/view/cdc/162213). Similarly, coverage with all vaccines was lower among children living below the federal poverty level than among those living at or above the poverty level, with percentage point differences ranging from 2.7 (≥1 dose of MMR) to 19.9 (≥2 doses of influenza vaccine) (Supplementary Table 2, https://stacks.cdc.gov/view/cdc/162214). No differences in coverage were observed between children living in a metropolitan statistical area (MSA)††† principal city and those living in an MSA nonprincipal city. However, coverage was lower among children living in a non-MSA compared with an MSA principal city for all vaccines except the full Hib series, the HepB birth dose, and ≥2 doses of HepA. Substantial jurisdictional variation in coverage estimates was also observed with selected vaccines (Table 3), especially ≥2-dose influenza vaccination coverage, which ranged from 25.6% in Mississippi to 80.3% in Rhode Island. Comparing the 2018–2019 and 2020–2021 birth cohorts by jurisdiction for each of eight vaccine measures identified 69 statistically significant differences in coverage estimates, 64 (92.8%) of which reflected lower vaccination coverage among the more recent (2020–2021) birth cohorts.
Discussion
Estimated coverage with most of the routinely recommended childhood vaccines monitored by NIS-Child by age 24 months was lower among children born in 2020 and 2021 compared with coverage among those born in 2018 and 2019. The Healthy People 2030§§§ objective to reduce the proportion of children receiving no vaccines by age 24 months (≤1.3%) has been met, but the objectives for ≥1 dose of MMR (≥90.8%) and ≥4 doses of DTaP (≥90.0%) have not. After increasing for several years, coverage with ≥2 doses of influenza vaccine among children born in 2021 declined to 53.4%, more than 10 percentage points below the estimated 63.8% coverage for the 2019 birth cohort. Several studies have documented a negative effect associated with the COVID-19 pandemic on routine pediatric vaccination (2–4) that could have affected children born in 2020 and 2021. However, analyses of NIS-Child data for children born during 2017–2020 did not identify any consistent or persistent declines in vaccination coverage at the national level and only a few decreases among population subgroups.¶¶¶ A recent analysis of trends in parental vaccine hesitancy during 2019–2022 found an increase in hesitancy among parents of children aged 5–11 years after authorization of COVID-19 vaccine, but not among parents of those aged 6 months–4 years (5). Parental vaccine hesitancy might be contributing to the low levels of influenza vaccination coverage, due to a higher degree of hesitancy among parents about influenza vaccine compared with other routine childhood vaccines. Hesitancy about influenza vaccine has been observed to be more highly correlated with hesitancy about COVID-19 vaccine than with other childhood vaccines, indicating that parents might perceive influenza vaccine differently than they do other routine non–COVID-19 childhood vaccines (6).
This report documents persistent disparities in childhood vaccination coverage by race and ethnicity, poverty status, MSA status, and health insurance status. Vaccination coverage is lower among Black, Hispanic, and AI/AN children, those insured by Medicaid or other nonprivate insurance, children who are uninsured, children living in more rural areas, and children in families with incomes below the federal poverty level. Disparities such as these have been described in other analyses of NIS-Child data (7,8). In addition to parental vaccine hesitancy, adoption of nonstandard vaccination schedules, and increasing use of religious and philosophical belief exemptions are other significant barriers to the achievement of complete childhood immunization (9).
Limitations
The findings in this report are subject to at least three limitations. First, the low household interview response rates (21%–27% during survey years 2019–2023) and the availability of adequate provider data for only 48%–54% of those with completed interviews during those survey years increases the possibility of selection bias. Such bias might persist to some degree even after survey weighting adjustments, potentially resulting in under- or overestimation of vaccination coverage. Second, potential bias related to noncoverage of households without telephones might also have been incompletely controlled for by the use of weighting in the analysis. If phoneless households are more common among lower income families, the result would be higher observed vaccination coverage. Finally, incompleteness of provider-reported vaccination histories during the most recent survey year could have biased coverage estimates downward. Contractual issues led to a shortened time frame for collecting information from vaccination providers, likely resulting in underascertainment of some administered vaccines. In addition, the vaccination history questionnaire mailed to providers was changed from one to two pages, possibly leading to additional reporting errors owing to lack of familiarity with the new questionnaire format. Assessment of total survey error for the 2023 survey year demonstrated that coverage was underestimated by 2.0 percentage points for ≥1 dose of MMR, 4.3 percentage points for the HepB birth dose, 5.1 percentage points for ≥4 doses of DTaP, and 9.4 percentage points for the combined seven-vaccine series.**** An analysis that evaluated coverage in children from the same monthly birth cohorts who appeared in two different survey years indicated 2–3 percentage point lower estimates based on the 2023 compared with the 2022 samples, indicating a possible change in bias between 2022 and 2023, consistent with the lower provider response rates in 2023.
Implications for Public Health Practice
Recent decreases in coverage with most of the ACIP-recommended childhood vaccines could lead to a resurgence of vaccine-preventable diseases such as measles, varicella, and rotavirus and their associated morbidity and mortality. During January 1–August 15, 2024, a total of 219 measles cases were reported in the United States, exceeding the number of cases reported annually during 2020–2023 (range = 13 (2020)–121 (2022)). Of the 219 cases in 2024, 190 (86%) were among persons who were unvaccinated or had unknown vaccination status.†††† Because children born during or after the period of major disruption of primary care from the COVID-19 pandemic might have missed some vaccinations, providers should review children’s histories and recommend needed vaccinations during every clinical encounter. Addressing financial barriers and other access issues along with vaccine hesitancy and misinformation concerns is important to increasing vaccination coverage and reducing disparities. Higher provider participation in the Vaccines for Children (VFC)§§§§ program would help to alleviate some of the financial barriers by increasing access to no-cost vaccines. Other activities that have been found to be effective include reminder/recall systems, implementation of standing orders and clinician prompts, encouraging providers to make strong vaccination recommendations to patients, administering vaccines in alternative settings, and coordination with Immunization Information Systems to identify communities with suboptimal vaccination coverage (8,10). Implementation of these interventions can increase vaccination coverage, reduce disparities, and bring the nation closer to eliminating vaccine-preventable diseases for all young children.
1Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC.
References
Wodi AP, Murthy N, McNally V, Cineas S, Ault K. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2023. MMWR Morb Mortal Wkly Rep 2023;72:137–40. https://doi.org/10.15585/mmwr.mm7206a1 PMID:36757872
Treharne A, Patel Murthy B, Zell ER, et al. Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions. Vaccine 2024;42:125997. https://doi.org/10.1016/j.vaccine.2024.05.045 PMID:38797629
Lv SR, Wang MK, Yu XL, Li XY, Yang JS. Impact of COVID-19 pandemic on routine childhood vaccinations. World J Virol 2024;13:90271. https://doi.org/10.5501/wjv.v13.i2.90271 PMID:38984085
Kujawski SA, Yao L, Wang HE, Carias C, Chen YT. Impact of the COVID-19 pandemic on pediatric and adolescent vaccinations and well child visits in the United States: a database analysis. Vaccine 2022;40:706–13. https://doi.org/10.1016/j.vaccine.2021.12.064 PMID:35012776
Vashist K, Yankey D, Elam-Evans LD, et al. Changes in vaccine hesitancy among parents of children aged 6 months–17 years, National Immunization Surveys, 2019–2022. Vaccine 2024;42:125989. https://doi.org/10.1016/j.vaccine.2024.05.037 PMID:38806351
Santibanez TA, Black CL, Zhou T, Srivastav A, Singleton JA. Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines. Vaccine 2024;42:126139. https://doi.org/10.1016/j.vaccine.2024.07.040 PMID:39019662
Hill HA, Yankey D, Elam-Evans LD, Chen M, Singleton JA. Vaccination coverage by age 24 months among children born in 2019 and 2020—National Immunization Survey-Child, United States, 2020–2022. MMWR Morb Mortal Wkly Rep 2023;72:1190–6. https://doi.org/10.15585/mmwr.mm7244a3 PMID:37917561
Valier MR, Yankey D, Elam-Evans LD, et al. Vital signs: trends and disparities in childhood vaccination coverage by Vaccines for Children Program eligibility—National Immunization Survey-Child, United States, 2012–2022. MMWR Morb Mortal Wkly Rep 2024;73:722–30. https://doi.org/10.15585/mmwr.mm7333e1 PMID:39173180
Carter-Pokras O, Hutchins S, Gaudino JA, et al. The role of epidemiology in informing United States childhood immunization policy and practice. Ann Epidemiol 2021;62:100–14. https://doi.org/10.1016/j.annepidem.2020.09.017 PMID:33065268
Michels SY, Daley MF, Newcomer SR. Completion of multidose vaccine series in early childhood: current challenges and opportunities. Curr Opin Infect Dis 2024;37:176–84. https://doi.org/10.1097/QCO.0000000000001007 PMID:38427536
TABLE 1. Estimated vaccination coverage, by age 24 months* among children born during 2018–2019 and 2020–2021 for selected vaccines and doses — National Immunization Survey-Child, United States, 2019–2023
Vaccine/Dose
% (95% CI)
Birth year†
Difference
(2018–2019 to 2020–2021)
2018–2019
2020–2021
DTaP§
≥3 doses
94.3 (93.8 to 94.7)
92.5 (91.8 to 93.2)
−1.8 (−2.6 to −1.0)¶
≥4 doses
81.8 (81.0 to 82.6)
79.3 (78.2 to 80.4)
−2.5 (−3.8 to −1.1)¶
Poliovirus (≥3 doses)
93.4 (92.9 to 93.9)
91.9 (91.2 to 92.6)
−1.5 (−2.4 to −0.6)¶
MMR (≥1 dose)**
92.0 (91.4 to 92.6)
90.3 (89.6 to 91.0)
−1.7 (−2.6 to −0.7)¶
Hib††
Primary series
93.8 (93.3 to 94.3)
91.6 (90.8 to 92.3)
−2.2 (−3.1 to −1.3)¶
Full series
80.0 (79.2 to 80.9)
76.8 (75.7 to 77.9)
−3.2 (−4.6 to −1.8)¶
HepB
Birth dose§§
80.3 (79.4 to 81.1)
79.5 (78.5 to 80.5)
−0.8 (−2.1 to 0.6)
≥3 doses
92.6 (92.0 to 93.1)
91.1 (90.3 to 91.8)
−1.5 (−2.4 to −0.6)¶
VAR (≥1 dose)**
91.2 (90.5 to 91.8)
89.9 (89.1 to 90.6)
−1.3 (−2.2 to −0.3)¶
PCV
≥3 doses
93.4 (92.9 to 93.9)
91.6 (90.9 to 92.3)
−1.8 (−2.6 to −0.9)¶
≥4 doses
83.4 (82.7 to 84.2)
80.7 (79.6 to 81.8)
−2.7 (−4.1 to −1.4)¶
HepA¶¶
≥1 dose
88.1 (87.4 to 88.8)
86.5 (85.6 to 87.4)
−1.6 (−2.7 to −0.4)¶
≥2 doses (by age 24 mos)
47.6 (46.5 to 48.6)
46.0 (44.8 to 47.2)
−1.6 (−3.2 to 0)
≥2 doses (by age 35 mos)
79.8 (78.6 to 81.0)
77.7 (76.1 to 79.2)
−2.1 (−4.1 to −0.1)¶
Rotavirus (by age 8 mos)***
77.1 (76.2 to 78.0)
75.1 (74.0 to 76.2)
−2.0 (−3.4 to −0.5)¶
Influenza (≥2 doses)†††
63.4 (62.4 to 64.4)
55.6 (54.4 to 56.8)
−7.8 (−9.4 to −6.2)¶
Combined seven-vaccine series§§§
70.1 (69.2 to 71.1)
66.9 (65.7 to 68.2)
−3.2 (−4.8 to −1.6)¶
No vaccinations¶¶¶
0.9 (0.8 to 1.1)
1.2 (1.0 to 1.4)
0.2 (0 to 0.5)
TABLE 2. Estimated vaccination coverage, by age 24 months* among children born during 2020–2021,† by selected vaccines and doses and race and ethnicity§ — National Immunization Survey–Child, United States, 2021–2023
Vaccine/Dose
Race and ethnicity,§ % (95% CI)
White (referent)
n = 16,656
Black or African American
n = 2,324
Hispanic or Latino
n = 5,331
AI/AN
n = 316
Asian
n = 1,460
NH/PI
n = 89
Multiple races
n = 2,492
DTaP¶
≥3 doses
92.8
(91.8–93.6)
92.1
(90.0–94.0)
92.9
(91.5–94.1)
87.9
(82.0–92.6)
92.8
(89.2–95.6)
88.0
(76.6–95.5)
90.8
(88.1–93.2)
≥4 doses
81.4
(80.1–82.6)
76.1
(72.3–79.6)**
77.5
(74.8–80.0)**
72.4
(64.2–80.1)**
83.1
(78.8–86.9)
—††
78.5
(75.1–81.8)
Poliovirus (≥3 doses)
92.2
(91.2–93.1)
91.6
(89.3–93.5)
92.1
(90.5–93.5)
88.9
(83.2–93.3)
92.2
(88.6–95.1)
88.0
(76.6–95.5)
90.3
(87.6–92.6)
MMR (≥1 dose)§§
90.2
(89.2–91.1)
89.2
(87.1–91.2)
91.3
(89.7–92.7)
87.7
(81.5–92.7)
91.8
(88.4–94.6)
—††
88.8
(85.8–91.4)
Hib¶¶
Primary series
91.8
(90.7–92.8)
91.0
(88.8–93.0)
92.2
(90.8–93.4)
86.1
(79.2–91.6)
91.5
(87.8–94.4)
87.0
(75.9–94.6)
89.9
(87.0–92.5)
Full series
77.9
(76.5–79.3)
73.7
(70.1–77.3)**
76.1
(73.6–78.5)
72.2
(64.0–79.9)
80.6
(76.5–84.3)
—††
76.4
(72.9–79.8)
HepB
Birth dose***
79.3
(78.0–80.6)
77.6
(74.3–80.6)
79.7
(77.3–81.9)
78.6
(69.4–85.6)
81.7
(77.6–85.2)
—††
82.0
(78.6–85.0)
≥3 doses
91.0
(90.0–91.9)
91.2
(89.0–93.2)
91.3
(89.5–92.9)
90.6
(85.4–94.4)
91.6
(88.7–94.1)
—††
90.0
(87.4–92.4)
VAR (≥1 dose)§§
89.8
(88.7–90.7)
90.0
(88.0–91.8)
91.0
(89.3–92.4)
83.0
(74.6–89.9)
88.6
(84.8–91.9)
89.1
(77.9–96.1)
88.1
(85.0–90.8)
PCV
≥3 doses
91.7
(90.7–92.7)
91.3
(89.0–93.3)
92.5
(91.2–93.7)
85.1
(77.2–91.4)
90.8
(87.1–93.8)
87.4
(75.9–95.1)
90.0
(87.1–92.5)
≥4 doses
83.1
(81.8–84.3)
77.9
(74.2–81.4)**
78.4
(76.0–80.8)**
74.2
(65.6–82.1)**
83.0
(79.0–86.7)
—††
80.2
(76.9–83.3)
HepA†††
≥1 dose
86.4
(85.2–87.5)
83.9
(80.4–87.1)
87.5
(85.4–89.4)
81.9
(74.7–88.1)
88.6
(85.1–91.6)
—††
87.2
(84.2–89.9)
≥2 doses (by age 24 mos)
47.3
(45.8–48.8)
40.5
(37.1–44.2)**
45.8
(43.0–48.7)
40.9
(32.2–51.0)
49.5
(44.9–54.3)
—††
47.6
(43.7–51.7)
≥2 doses (by age 35 mos)
79.8
(78.0–81.6)
72.7
(67.4–77.8)**
76.1
(72.6–79.4)
—††
81.2
(74.5–87.0)
—††
79.1
(74.0–83.9)
Rotavirus (by age 8 mos)§§§
77.3
(76.0–78.6)
71.4
(67.7–74.7)**
72.9
(70.3–75.4)**
67.2
(57.6–75.5)**
79.7
(75.6–83.3)
—††
75.5
(71.6–79.0)
Influenza ≥2 doses¶¶¶
59.6
(58.0–61.1)
42.6
(39.0–46.3)**
52.8
(49.9–55.7)**
51.5
(42.7–61.1)
71.4
(66.9–75.8)**
—††
55.6
(51.8–59.5)
Combined seven-vaccine series****
68.8
(67.3–70.2)
64.0
(60.2–67.8)**
65.0
(62.1–67.8)**
58.7
(49.7–67.9)**
70.0
(65.4–74.5)
—††
67.9
(64.2–71.6)
No vaccinations
1.4
(1.2–1.7)
0.9
(0.6–1.3)**
1.0
(0.7–1.4)
—††
—††
—††
—††
TABLE 3. Estimated vaccination coverage with selected individual vaccines and a combined vaccine series,* by age 24 months† among children born during 2020–2021,§ by U.S. Department of Health and Human Services region, state, selected local area, and territory — National Immunization Survey-Child, United States, 2021–2023
U.S. national, HHS region, state or local area, or territory
No.
Vaccine/Vaccine series, % (95% CI)
MMR¶
(≥1 dose)
Poliovirus
DTaP**
(≥4 doses)
HepB††
(birth dose)
HepA
(≥2 doses by age 35 mos)
Rotavirus§§
Influenza¶¶
(≥2 doses)
Combined
seven-vaccine series*
U.S. national
28,668
90.3
(89.6–91.0)***
91.9
(91.2–92.6)***
79.3
(78.2–80.4)***
79.5
(78.5–80.5)
77.7
(76.1–79.2)***
75.1
(74.0–76.2)***
55.6
(54.4–56.8)***
66.9
(65.7–68.2)***
HHS Region 1
2,578
94.9
(92.9–96.5)
96.4
(95.1–97.5)
87.8
(85.1–90.2)
83.8
(80.7–86.6)
90.0
(85.3–93.6)
85.8
(83.4–88.0)
75.0
(71.3–78.5)***
79.6
(76.3–82.7)
Connecticut
412
94.4
(90.4–97.2)
95.4
(91.4–97.9)
86.7
(81.2–91.3)
83.9
(78.1–88.3)
91.2
(83.6–96.2)
84.5
(78.9–88.9)
79.8
(73.7–85.3)
76.7
(70.5–82.5)
Maine
366
94.2
(90.7–96.7)
95.5
(92.5–97.5)
86.1
(81.0–90.5)
82.8
(77.3–87.2)
80.2
(72.6–86.8)
75.8
(69.6–81.0)
73.0
(66.8–78.8)
74.4
(68.4–80.0)
Massachusetts
443
94.9
(91.0–97.5)
97.1
(94.8–98.6)
88.5
(83.6–92.4)
85.2
(78.9–89.8)
93.8
(83.7–98.6)
89.4
(85.1–92.6)†††
72.4
(65.7–78.8)***
83.1
(77.0–88.4)
New Hampshire
315
95.5
(92.6–97.6)
96.5
(93.6–98.3)
89.4
(84.4–93.4)
81.4
(75.3–86.2)
78.9
(70.4–86.4)
80.8
(74.6–85.7)
72.5
(66.1–78.5)
77.2
(70.9–82.9)
Rhode Island
542
95.8
(93.1–97.7)
96.3
(93.4–98.2)
88.3
(84.1–91.7)
81.6
(76.6–85.8)
90.0
(82.4–95.2)
86.2
(81.4–89.9)
80.3
(75.4–84.8)
77.8
(72.8–82.3)
Vermont
500
95.2
(91.7–97.6)
95.6
(92.0–97.8)
86.4
(81.6–90.5)
78.6
(73.1–83.2)
84.9
(76.6–91.5)
82.0
(76.9–86.2)
75.7
(70.0–81.0)
75.6
(69.9–81.0)
HHS Region 2
1,462
89.6
(86.8–92.0)
92.8
(90.5–94.7)
82.1
(78.8–85.1)
78.0
(74.8–80.9)
73.7
(68.5–78.7)
74.8
(71.4–77.9)
62.1
(58.4–65.7)***
67.5
(64.0–71.1)
New Jersey
436
89.3
(83.6–93.7)
93.4
(89.2–96.3)
83.0
(76.8–88.4)
81.5
(76.0–86.0)
76.9
(67.0–85.5)
75.0
(68.6–80.4)
64.5
(58.0–70.9)***
63.7
(57.0–70.3)
New York
1,026
89.7
(86.6–92.3)***
92.5
(89.6–94.8)
81.6
(77.7–85.2)
76.3
(72.3–79.8)
72.2
(66.1–78.0)
74.7
(70.6–78.4)
60.8
(56.4–65.2)***
69.5
(65.3–73.6)
New York City
560
86.7
(82.1–90.6)***
92.0
(87.8–95.1)
80.7
(75.3–85.6)
72.8
(67.1–77.8)
68.7
(59.9–77.1)
73.3
(67.5–78.4)
62.2
(56.2–68.2)
68.0
(62.1–73.8)
New York, excluding New York City
466
92.1
(87.7–95.4)
92.9
(88.6–96.0)
82.3
(76.7–87.3)
79.2
(73.4–84.0)
75.0
(66.6–82.7)
75.9
(69.9–81.0)
59.6
(53.3–66.0)***
70.8
(64.8–76.5)
HHS Region 3
3,970
89.9
(88.0–91.6)***
92.1
(90.5–93.6)
80.5
(78.1–82.7)
80.0
(77.7–82.1)***
79.6
(76.2–82.8)
77.7
(75.3–79.9)
62.5
(59.8–65.2)***
69.0
(66.5–71.6)***
Delaware
293
91.0
(86.3–94.6)
90.5
(85.6–94.3)
81.1
(74.8–86.6)
80.7
(74.2–85.9)
84.9
(75.2–92.3)
71.1
(63.7–77.5)
58.7
(51.3–66.2)***
68.1
(60.9–75.1)
District of Columbia
463
88.4
(83.0–92.7)
90.1
(85.2–94.0)
80.3
(73.7–86.1)
78.2
(71.6–83.6)
74.5
(64.8–83.3)
75.9
(69.0–81.6)
67.9
(60.5–75.2)
71.2
(64.3–77.9)
Maryland
861
95.4
(93.0–97.1)
96.0
(93.7–97.7)
87.3
(83.7–90.5)
80.0
(75.6–83.8)
86.5
(80.9–91.1)
82.0
(77.9–85.5)
66.5
(61.9–71.1)
75.7
(71.4–79.9)
Pennsylvania
1,121
88.6
(85.0–91.6)***
91.2
(88.2–93.7)
77.9
(73.5–82.1)
83.5
(79.6–86.8)
78.8
(72.4–84.6)
79.0
(74.8–82.6)
61.7
(56.6–66.8)***
67.1
(62.4–71.9)***
Philadelphia
546
89.7
(85.2–93.3)
88.8
(84.2–92.6)
76.3
(70.4–81.9)
82.2
(76.8–86.5)
79.7
(71.1–87.1)
75.0
(69.0–80.1)
62.9
(56.7–69.0)
65.5
(59.2–71.7)
Pennsylvania, excluding Philadelphia
575
88.4
(84.3–91.9)***
91.6
(88.1–94.4)
78.2
(73.1–83.0)
83.8
(79.2–87.5)
78.7
(71.3–85.3)
79.7
(74.8–83.8)
61.5
(55.7–67.3)***
67.4
(61.9–72.9)
Virginia
804
88.0
(84.1–91.4)
91.6
(88.0–94.5)
79.8
(75.1–84.2)
75.2
(70.3–79.6)
75.3
(68.8–81.4)
74.7
(69.3–79.4)
63.7
(58.5–68.9)***
67.8
(62.8–72.7)***
West Virginia
428
87.6
(82.4–91.9)
88.3
(83.4–92.3)***
74.2
(68.2–79.9)
80.0
(74.2–84.7)
76.6
(69.7–83.0)
72.3
(65.8–78.0)
46.5
(40.6–52.9)
63.2
(57.0–69.4)
HHS Region 4
4,478
89.7
(88.2–91.2)***
92.2
(90.8–93.5)
79.6
(77.5–81.6)
78.5
(76.5–80.5)
76.3
(73.0–79.5)
72.7
(70.4–74.8)
43.0
(40.6–45.4)***
66.0
(63.6–68.3)***
Alabama
400
89.8
(84.6–93.8)
89.2
(83.8–93.4)
79.7
(73.6–85.2)
76.7
(70.3–82.1)
75.3
(66.9–82.9)
69.8
(62.6–76.1)
33.4
(27.2–40.5)
62.6
(55.7–69.5)
Florida
666
90.8
(87.2–93.8)
91.6
(87.9–94.5)
80.1
(75.0–84.8)
76.3
(71.1–80.8)
76.1
(67.0–84.2)
70.9
(65.3–75.9)
42.1
(36.5–48.1)
67.3
(61.5–72.9)
Georgia
593
84.3
(79.2–88.7)***
91.5
(87.8–94.5)
76.4
(70.8–81.5)
79.4
(74.1–83.8)
76.0
(67.7–83.5)
70.9
(64.8–76.3)
40.4
(34.6–46.7)
64.3
(58.3–70.3)
Kentucky
540
88.5
(84.0–92.1)
91.9
(87.9–94.9)
79.3
(73.9–84.2)
79.8
(74.8–84.1)
77.6
(70.8–83.7)
69.2
(63.6–74.4)***
45.9
(40.3–51.9)***
64.1
(58.3–69.9)***
Mississippi
505
87.9
(82.6–92.2)
88.0
(82.4–92.4)
74.3
(67.7–80.5)
79.0
(73.1–83.9)
—§§§
62.2
(55.3–68.6)
25.6
(20.7–31.3)***
64.8
(58.0–71.6)
North Carolina
764
94.1
(91.6–96.1)
96.6
(94.9–97.9)
81.4
(77.1–85.4)
84.9
(80.9–88.2)
76.5
(70.5–82.0)
80.0
(75.4–83.9)
49.5
(44.3–54.9)***
69.7
(64.7–74.5)
South Carolina
431
88.7
(83.8–92.7)
90.2
(85.5–93.9)
77.7
(71.8–83.1)
80.2
(74.7–84.8)
—§§§
78.1
(71.9–83.3)
37.8
(32.2–43.9)
64.5
(58.2–70.6)
Tennessee
579
91.1
(87.0–94.3)
93.9
(90.5–96.5)
83.3
(78.2–87.7)
73.0
(67.1–78.2)
83.9
(74.6–91.2)
74.2
(68.5–79.2)
55.7
(49.7–61.9)***
64.4
(58.4–70.3)
HHS Region 5
3,717
91.8
(90.4–93.1)
92.5
(91.1–93.7)
80.7
(78.7–82.7)
81.4
(79.4–83.1)
80.1
(77.1–82.9)
75.8
(73.7–77.8)
60.2
(57.9–62.5)***
68.7
(66.5–70.9)
Illinois
918
92.7
(89.6–95.1)
93.2
(90.4–95.3)
80.0
(75.9–83.8)
79.2
(75.2–82.8)
76.3
(70.1–82.0)
74.9
(70.6–78.8)
58.7
(54.2–63.2)
66.4
(62.0–70.7)
Chicago
280
91.6
(86.9–95.1)
91.9
(86.9–95.5)
81.8
(75.3–87.5)
81.6
(74.6–86.9)
74.2
(64.0–83.4)
75.9
(68.2–82.2)
64.4
(56.7–72.2)
63.9
(56.3–71.5)
Illinois, excluding Chicago
638
93.0
(89.1–95.9)
93.5
(90.2–96.0)
79.5
(74.5–84.1)
78.6
(73.7–82.8)
76.6
(69.3–83.3)
74.6
(69.4–79.2)
57.0
(51.7–62.4)
67.2
(61.9–72.4)
Indiana
369
91.9
(87.7–95.1)
93.5
(89.5–96.4)
81.7
(75.8–86.9)
81.4
(75.2–86.3)
80.1
(70.1–88.4)
72.7
(65.9–78.5)
50.5
(44.0–57.4)***
71.7
(65.3–77.8)
Michigan
771
93.4
(89.9–95.9)
92.4
(89.1–95.1)***
78.6
(73.3–83.5)
78.3
(73.3–82.6)
80.8
(74.4–86.5)***
78.7
(73.8–82.9)
64.4
(58.8–69.9)
67.7
(62.3–73.0)
Minnesota
415
92.0
(87.6–95.3)
92.8
(88.6–95.9)
82.0
(75.9–87.4)
81.3
(75.0–86.4)
—§§§
77.2
(70.7–82.6)
68.0
(61.5–74.3)
68.9
(62.4–75.3)
Ohio
759
90.2
(86.9–93.0)
91.5
(88.4–94.1)
82.0
(77.6–86.0)
84.8
(80.9–88.1)
80.3
(74.2–85.7)
74.9
(70.1–79.3)
56.4
(51.3–61.6)***
69.9
(65.1–74.5)
Wisconsin
485
90.9
(86.9–94.1)
91.1
(87.1–94.3)
80.0
(74.7–84.8)
83.8
(78.4–88.0)
85.6
(78.9–91.0)
77.6
(72.0–82.3)
69.1
(63.2–74.8)
68.4
(62.7–74.0)
HHS Region 6
3,492
91.7
(89.7–93.4)
91.8
(89.6–93.7)
79.5
(76.1–82.7)
81.6
(78.4–84.4)
78.3
(73.5–82.7)
75.7
(72.0–79.1)
48.7
(44.6–52.9)***
66.6
(62.7–70.5)
Arkansas
513
86.6
(80.9–91.2)
86.5
(81.0–91.1)
73.4
(67.0–79.5)
82.9
(77.5–87.3)
79.4
(71.2–86.6)
73.4
(67.1–78.9)
40.4
(34.0–47.5)
62.0
(55.4–68.6)
Louisiana
697
90.7
(87.1–93.7)
93.0
(89.6–95.6)
81.3
(76.4–85.8)†††
76.8
(71.8–81.2)
72.6
(65.0–79.7)
74.3
(68.9–79.1)†††
40.8
(35.5–46.6)
68.5
(62.7–74.0)
New Mexico
595
89.6
(85.2–93.2)***
90.1
(85.9–93.5)***
76.7
(71.1–81.8)
74.4
(69.1–79.1)
77.4
(70.7–83.5)
75.1
(69.6–79.9)***
55.4
(49.7–61.3)***
68.2
(62.5–73.7)
Oklahoma
446
88.0
(83.2–92.0)
92.6
(89.0–95.4)
78.2
(72.5–83.4)
77.2
(71.5–82.1)
78.5
(71.3–85.0)
73.9
(68.2–78.9)
44.0
(38.0–50.5)
64.9
(58.7–71.1)
Texas
1,241
92.8
(90.2–95.0)
92.1
(88.9–94.6)
80.0
(75.2–84.3)
83.1
(78.5–86.9)
79.3
(72.2–85.5)
76.4
(71.1–80.9)
50.8
(45.1–56.7)
66.8
(61.4–72.2)
Bexar County
313
86.4
(81.1–90.8)
88.2
(82.8–92.6)
76.9
(70.1–83.0)
73.4
(65.7–80.0)
73.5
(63.7–82.4)
73.1
(65.4–79.6)
47.7
(40.0–56.2)***
62.3
(54.5–70.1)
Houston
339
87.8
(82.1–92.3)
90.8
(85.4–94.9)
73.9
(66.2–81.0)
79.7
(72.9–85.1)
—§§§
75.4
(67.7–81.8)
56.8
(49.1–64.8)
65.7
(57.9–73.4)
Texas, excluding Bexar County and Houston
589
94.1
(90.9–96.5)
92.6
(88.7–95.5)
81.2
(75.4–86.3)
84.4
(78.8–88.8)
79.3
(70.8–86.7)
76.8
(70.4–82.2)
50.2
(43.4–57.4)
67.4
(60.8–73.8)
HHS Region 7
2,168
91.3
(89.4–92.9)
92.5
(90.8–94.1)
80.6
(77.9–83.2)
82.4
(79.9–84.6)
80.8
(76.8–84.5)
78.7
(76.0–81.2)
54.8
(51.7–57.9)***
67.5
(64.5–70.6)
Iowa
455
90.2
(85.2–94.0)***
92.7
(88.4–95.8)
80.4
(74.1–85.9)***
82.8
(77.1–87.4)
81.3
(71.4–89.3)
79.4
(73.0–84.6)
45.8
(39.4–52.8)
70.9
(64.2–77.3)***
Kansas
634
90.1
(86.2–93.2)
90.4
(86.7–93.4)
77.6
(72.3–82.4)
77.5
(72.1–82.1)
81.7
(73.7–88.4)
75.6
(70.1–80.4)
55.0
(49.5–60.7)
66.4
(60.9–71.9)
Missouri
657
91.7
(88.6–94.3)
92.9
(89.9–95.3)
79.7
(74.9–84.1)
85.0
(81.1–88.2)
80.1
(73.2–86.2)
79.7
(75.2–83.6)†††
54.0
(48.7–59.5)
68.6
(63.3–73.8)
Nebraska
422
93.6
(89.5–96.5)
94.7
(91.5–96.9)
88.2
(83.4–92.2)
81.3
(75.0–86.3)
81.9
(74.5–88.1)
79.4
(73.7–84.2)
70.5
(63.9–76.9)
61.2
(54.5–68.0)***
HHS Region 8
2,759
88.4
(85.9–90.6)***
90.7
(88.5–92.6)***
78.5
(75.6–81.2)***
81.1
(78.4–83.5)
79.0
(75.0–82.7)
73.7
(70.6–76.6)***
64.0
(60.8–67.2)***
68.0
(64.9–71.1)***
Colorado
482
86.0
(80.8–90.3)***
88.9
(84.1–92.7)***
77.0
(71.4–82.2)
80.5
(75.0–85.0)
78.8
(71.1–85.6)
71.9
(65.8–77.3)***
67.8
(61.9–73.6)
66.1
(60.2–71.9)
Montana
347
86.3
(81.6–90.4)
89.7
(85.4–93.2)
69.6
(63.2–75.7)***
71.7
(65.2–77.3)
62.7
(53.8–71.5)
65.5
(58.8–71.6)***
54.8
(48.3–61.6)***
57.8
(51.2–64.5)***
North Dakota
391
87.0
(81.6–91.5)***
90.3
(86.0–93.7)***
77.3
(70.9–83.1)***
86.9
(81.6–90.9)
79.7
(71.2–87.1)
77.6
(71.0–83.0)
67.3
(60.5–74.0)
71.9
(65.1–78.3)***
South Dakota
483
89.9
(84.9–93.8)
87.8
(82.0–92.4)***
71.9
(64.8–78.6)
81.8
(75.2–86.8)
82.6
(72.3–90.8)
76.6
(69.5–82.4)
62.9
(55.6–70.2)***
63.9
(56.6–71.1)
Utah
559
91.8
(88.2–94.7)
94.1
(91.7–96.0)
84.7
(80.4–88.5)
83.8
(79.3–87.5)
82.8
(77.2–87.7)
76.4
(71.1–81.0)***
62.1
(56.6–67.7)***
74.0
(68.7–79.0)
Wyoming
497
89.6
(84.8–93.4)
90.4
(86.1–93.8)
76.1
(70.0–81.7)
74.5
(68.2–79.8)
69.0
(61.3–76.3)
77.0
(71.1–82.0)
54.3
(47.9–60.9)
65.2
(58.8–71.5)
HHS Region 9
2,037
88.2
(84.8–91.1)***
89.5
(86.2–92.3)***
73.2
(68.2–77.9)***
74.1
(69.5–78.2)
73.5
(67.5–79.2)
72.5
(67.8–76.7)
57.8
(53.1–62.7)***
60.7
(55.8–65.7)***
Arizona
437
85.6
(80.3–90.1)***
88.2
(83.1–92.4)***
75.7
(69.3–81.6)***
80.5
(74.3–85.5)
76.2
(65.7–85.4)
69.6
(62.8–75.7)
48.8
(42.2–55.9)***
62.9
(56.3–69.5)***
California
687
88.6
(84.3–92.3)
89.8
(85.6–93.2)***
72.4
(66.1–78.5)***
72.2
(66.3–77.4)
73.7
(66.1–80.7)
73.1
(67.1–78.4)
60.6
(54.5–66.8)***
59.8
(53.6–66.1)***
Hawaii
353
87.6
(83.1–91.4)
88.9
(84.4–92.6)
81.4
(76.1–86.1)
83.9
(78.8–88.0)
73.1
(64.5–81.1)
73.1
(66.6–78.8)
62.7
(56.3–69.2)
69.1
(62.9–75.1)
Nevada
560
87.9
(83.2–91.8)
88.7
(84.0–92.6)
72.1
(66.2–77.8)***
77.8
(72.0–82.6)
70.0
(62.0–77.6)
70.3
(64.6–75.5)
42.5
(37.1–48.3)***
63.1
(57.1–69.0)***
HHS Region 10
2,007
90.0
(87.7–92.0)
91.0
(88.8–92.9)***
78.5
(75.4–81.4)***
83.3
(80.7–85.6)
78.9
(74.5–83.1)
75.0
(71.8–77.9)***
63.5
(60.1–66.8)***
69.2
(65.9–72.4)
Alaska
492
83.9
(78.9–88.3)
87.0
(82.1–91.1)
72.6
(66.5–78.3)
73.4
(67.7–78.4)
—§§§
71.2
(65.4–76.4)
57.6
(51.7–63.7)
59.8
(53.8–65.9)
Idaho
457
88.9
(84.0–92.8)
88.0
(82.5–92.4)
77.1
(71.0–82.8)
83.9
(78.5–88.1)†††
76.8
(66.9–85.5)
75.7
(69.2–81.3)
56.4
(49.8–63.2)
69.4
(63.0–75.6)
Oregon
351
89.0
(84.1–92.9)
90.6
(85.8–94.3)
77.1
(70.7–83.0)
83.1
(77.6–87.5)
80.7
(70.4–89.2)
71.7
(65.0–77.5)
59.9
(53.3–66.6)***
64.3
(57.5–71.0)
Washington
707
91.1
(87.7–93.9)
92.4
(89.3–94.9)
80.1
(75.5–84.3)
84.2
(80.3–87.5)
79.0
(73.2–84.2)
76.8
(72.1–80.9)
67.7
(62.7–72.7)***
72.4
(67.6–77.0)
Range of column values
NA
83.9–95.8
86.5–97.1
69.6–89.4
71.7–86.9
62.7–93.8
62.2–89.4
25.6–80.3
57.8–83.1
Territory
Guam
161
77.3
(67.6–85.8)
—§§§
—§§§
84.4
(76.1–90.3)
—§§§
48.2
(38.4–58.2)
—§§§
—§§§
Puerto Rico
587
76.2
(70.8–81.3)†††
79.8
(74.8–84.5)
65.0
(59.0–70.9)†††
72.3
(66.4–77.5)
—§§§
61.5
(55.5–67.2)
16.8
(12.8–21.8)
53.5
(47.4–59.8)†††
U.S. Virgin Islands¶¶¶
58
—§§§
—§§§
—§§§
—§§§
—§§§
—§§§
—§§§
—§§§
Suggested citation for this article: Hill HA, Yankey D, Elam-Evans LD, et al. Decline in Vaccination Coverage by Age 24 Months and Vaccination Inequities Among Children Born in 2020 and 2021 — National Immunization Survey-Child, United States, 2021–2023. MMWR Morb Mortal Wkly Rep 2024;73:844–853. DOI: http://dx.doi.org/10.15585/mmwr.mm7338a3.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.